Denali Therapeutics Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Denali Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2016 to 2023.
  • Denali Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$107M, a 7.89% decline year-over-year.
  • Denali Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$427M, a 244% decline year-over-year.
  • Denali Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$145M, a 55.5% increase from 2022.
  • Denali Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$326M, a 12.2% decline from 2021.
  • Denali Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$291M, a 508% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$145M +$181M +55.5% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 -$326M -$35.4M -12.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 -$291M -$362M -508% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $71.1M +$269M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 -$198M -$161M -445% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 -$36.2M +$51.9M +58.9% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 -$88.2M -$1.53M -1.77% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 -$86.7M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.